Pharmaceuticals

Innovating to treat disease more effectively

Our global Pharmaceuticals portfolio includes more than 50 key marketed products, many of which are innovative leaders in their therapeutic areas. In 2009 we received a total of 25 positive regulatory decisions in the United States, Europe and Japan.

Key pharmaceutical products marketed by Novartis are listed below by therapeutic area.

Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your physician about any medical condition or prescription product.

Note that some product links are intended for US residents only.

Learn more about our Pharmaceuticals Division

A C D E F G I L M N P R S T V X Z

 

 

	Galvus (vildagliptin) Type 2 diabetes
	Gleevec/Glivec (imatinib mesylate/imatinib) Certain forms of chronic myeloid leukemia Certain forms of gastrointestinal stromal tumor Certain forms of acute lymphoblastic leukemia Dermatofibrosarcoma protuberans Hypereosinophilic syndrome Aggressive systemic mastocytosis Myelodysplastic/myeloproliferative diseases Visit www.glivec.com Visit www.gleevec.com (US residents only)